Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

[Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia].

León CA, Vigoya J, Conde S, Campo G, Castrillón E, León A.

Acta Psiquiatr Psicol Am Lat. 1994 Mar;40(1):41-9. Spanish.

PMID:
8053353
2.
3.

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

Freeman HL.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S11-7. Review.

PMID:
9218163
4.
5.

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.

Lecrubier Y, Boyer P, Turjanski S, Rein W.

J Affect Disord. 1997 Apr;43(2):95-103.

PMID:
9165379
6.

Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.

Kim SW, Shin IS, Kim JM, Lee SH, Lee JH, Yoon BH, Yang SJ, Hwang MY, Yoon JS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1504-9. Epub 2007 Jul 13.

PMID:
17692448
8.

A clinical and pharmacological study of the antidepressant activity of viloxazine in adult and elderly patients.

Tosca P, Zerbi F, Romani A, Molini G, Cairoli S, Montagna M, Gabba A, Groppi A.

Int J Clin Pharmacol Ther Toxicol. 1985 May;23(5):270-3.

PMID:
4008117
9.

Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study.

Maina G, Vitalucci A, Gandolfo S, Bogetto F.

J Clin Psychiatry. 2002 Jan;63(1):38-43.

PMID:
11838624
10.

Alcoholism and depression: a placebo controlled study with viloxazine.

Altamura AC, Mauri MC, Girardi T, Panetta B.

Int J Clin Pharmacol Res. 1990;10(5):293-8.

PMID:
2079386
11.

[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].

Chabannes JP, Pelissolo A, Farah S, Gerard D.

Encephale. 1998 Jul-Aug;24(4):386-92. French.

PMID:
9809244
12.

Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.

Montgomery SA.

Int Clin Psychopharmacol. 2002 Dec;17 Suppl 4:S9-15; discussion S16-7. Review.

PMID:
12685917
13.

A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.

Riedel M, Eich FX, Möller HJ.

Eur Psychiatry. 2009 Apr;24(3):149-53. doi: 10.1016/j.eurpsy.2008.10.005. Epub 2008 Dec 13.

PMID:
19070995
14.

Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study.

Petrie WM, McEvoy JP, Wilson WH, Ban TA, Guy W.

Int Pharmacopsychiatry. 1980;15(3):193-6.

PMID:
7016802
15.

Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.

McEvoy JP, Libiger J, Wilson WH, Ban TA, Berney S, Guy W.

J Clin Psychiatry. 1982 Mar;43(3):111-2.

PMID:
7037758
16.

Does viloxazine really improve sex drive? A double-blind controlled study.

De Leo D, Magni G.

Br J Psychiatry. 1986 May;148:597-9.

PMID:
3535972
17.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
18.

A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes.

Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F.

Psychiatry Res. 2002 Oct 10;112(2):145-52.

PMID:
12429360
20.

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.

Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G.

Pharmacopsychiatry. 2008 Jan;41(1):24-8. doi: 10.1055/s-2007-993209.

PMID:
18203048

Supplemental Content

Support Center